Evidence map›Paper›PMID 37236665›Full record

ArticleBMJ open2023

Uptake of four or more doses of sulfadoxine pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Zambia: findings from the 2018 malaria in pregnancy survey.

Danny Sinyange, Nawa Mukumbuta, Lwito Salifya Mutale, Hudson Mumbole, Busiku Hamainza, Cephas Sialubanje

Abstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Danny SinyangeSchool of Public Health, Levy Mwanawasa Medical University, Lusaka, Zambia.
Nawa MukumbutaSchool of Public Health, Levy Mwanawasa Medical University, Lusaka, Zambia.ORCID 0000-0003-2360-2752
Lwito Salifya MutaleZambia Field Epidemiology Training Program, Zambia National Public Health Institute, Lusaka, Zambia.
Hudson MumboleNational Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Busiku HamainzaNational Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Cephas SialubanjeSchool of Public Health, Levy Mwanawasa Medical University, Lusaka, Zambia csialubanje@yahoo.com.ORCID 0000-0002-9077-1436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the prevalence and predictors of the uptake of four or more doses of sulfadoxine pyrimethamine (IPTp-SP 4+) in Zambia.

designA cross-sectional study using secondary data from the malaria in pregnancy survey (Malaria Indicator Survey) data set conducted from April to May 2018.

settingThe primary survey was conducted at community level and covered all the 10 provinces of Zambia.

participantsA total of 3686 women of reproductive age (15-45 years) who gave birth within the 5 years before the survey. PRIMARY OUTCOME: Proportion of participants with four or more doses of IPTp-SP. STATISTICAL ANALYSIS: All analyses were conducted using RStudio statistical software V.4.2.1. Descriptive statistics were computed to summarise participant characteristics and IPTp-SP uptake. Univariate logistic regression was carried out to determine association between the explanatory and outcome variables. Explanatory variables with a p value less than 0.20 on univariate analysis were included in the multivariable logistic regression model and crude and adjusted ORs (aORs) along with their 95% CIs were computed (p<0.05).

resultsOf the total sample of 1163, only 7.5% of participants received IPTp-SP 4+. Province of residence and wealth tertile were associated with uptake of IPTp-SP doses; participants from Luapula (aOR=8.72, 95% CI (1.72 to 44.26, p=0.009)) and Muchinga (aOR=6.67, 95% CI (1.19 to 37.47, p=0.031)) provinces were more likely to receive IPTp-SP 4+ compared with to those from Copperbelt province. Conversely, women in the highest wealth tertile were less likely to receive IPTp-SP 4+ doses compared with those in the lowest quintile (aOR=0.32; 95% CI (0.13 to 0.79, p=0.014)).

conclusionThese findings confirm a low uptake of four or more doses of IPTp-SP in the country. Strategies should focus on increased coverage of IPTp-SP in provinces with much higher malaria burden where the risk is greatest and the ability to afford healthcare lowest.

Indexed as

AntimalarialsMalariaPregnancy Complications, ParasiticAdolescentAdultCross-Sectional StudiesDrug CombinationsFemaleHumansMiddle AgedPregnancyPyrimethamineSulfadoxineSurveys and QuestionnairesYoung AdultZambiaAntimalarialsDrug CombinationsPyrimethamineSulfadoxineEPIDEMIOLOGYHealth Services AccessibilityMaternal medicinePUBLIC HEALTH

Identifiers

PMID37236665
PMCPMC10231002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.